Teleflex Incorporated $TFX Shares Purchased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lifted its holdings in Teleflex Incorporated (NYSE:TFX) by 40.6% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 774,034 shares of the medical technology company’s stock after purchasing an additional 223,585 shares during the period. Thrivent Financial for Lutherans’ holdings in Teleflex were worth $94,463,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Ruffer LLP acquired a new position in Teleflex during the 4th quarter worth approximately $5,154,000. Waterfront Wealth Inc. acquired a new position in Teleflex during the 4th quarter worth approximately $2,050,000. Eos Management L.P. acquired a new position in Teleflex during the 4th quarter worth approximately $3,763,000. Capital International Investors acquired a new position in Teleflex during the 3rd quarter worth approximately $44,851,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in Teleflex by 227.5% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 27,822 shares of the medical technology company’s stock worth $3,395,000 after acquiring an additional 19,327 shares in the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Mizuho set a $140.00 price target on shares of Teleflex in a report on Friday, May 8th. Royal Bank Of Canada upgraded shares of Teleflex from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $135.00 to $155.00 in a research report on Friday, May 8th. Zacks Research upgraded shares of Teleflex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Needham & Company LLC boosted their price objective on shares of Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Wells Fargo & Company boosted their price objective on shares of Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $144.00.

Teleflex Stock Up 0.3%

Shares of NYSE:TFX opened at $130.42 on Friday. The stock has a market cap of $5.77 billion, a P/E ratio of -5.72, a P/E/G ratio of 0.97 and a beta of 0.82. The firm has a fifty day moving average price of $120.53 and a 200 day moving average price of $116.68. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03. Teleflex Incorporated has a 1-year low of $100.18 and a 1-year high of $139.67.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.18. The firm had revenue of $548.30 million during the quarter, compared to analysts’ expectations of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. Teleflex’s quarterly revenue was up 32.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.44 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Sell-side analysts predict that Teleflex Incorporated will post 6.7 EPS for the current year.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Friday, March 6th were given a dividend of $0.34 per share. The ex-dividend date was Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. Teleflex’s dividend payout ratio is presently -5.96%.

Trending Headlines about Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex beat first-quarter earnings and revenue expectations, which signals that near-term business performance is still holding up better than expected, even as the market digests margin pressure. TFX Stock Down Post Q1 Earnings & Revenue Beat, Margins Crash
• Positive Sentiment: Needham & Company reiterated a Buy rating and a $147 price target, suggesting confidence that Teleflex can deliver meaningful earnings growth over the next several years.
• Positive Sentiment: The company’s latest earnings outlook still implies growth from the current year to FY2027 and FY2028, which may help support investor sentiment despite the recent reset in estimates.
• Neutral Sentiment: Analysts at Citizens JMP and Needham released mostly constructive but varied quarterly projections for FY2026 and FY2027, indicating that expectations remain in flux following the earnings report.
• Negative Sentiment: Wolfe Research lowered Teleflex’s FY2026, FY2027, FY2028, FY2029 and FY2030 EPS estimates, reflecting a more cautious view on the company’s longer-term earnings trajectory.
• Negative Sentiment: The post-earnings reaction was hurt by steep margin declines and a 52.1% drop in operating profit, which raised concerns that revenue growth is not yet translating into strong profitability. TFX Stock Down Post Q1 Earnings & Revenue Beat, Margins Crash

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.